The Center for Bioinformatics and Biostatistics (CBB) provides support and knowledge on bioinformatics and biostatistics research methods. The goal is to improve opportunities for researchers at Campus Flemingsberg to use new research methods and provide training in existing methods.
The idea behind HappyPaws is an open platform that provides pet owners power over their pets’ medical records. It would give pet owners a better overview of their animals’ medical histories, from previous visits to the vet to the vaccination status, and allow information to be shared with other users.
Invest Stockholm has now updated its presentation of the region's research and the companies working with neurodegenerative diseases. Here you will find, among others, AlzeCure, which is developing a painkiller based on this year's Nobel Prize in Medicine.
“We’re developing a completely new drug to combat viral infections – an antiviral drug – using modern genetic engineering. Our methods are based on the Nobel-winning CRISPR technology that paves the way to new, targeted treatments,” says Theodor Pramer, CEO of Biomedrex Genetics.
Johnny Högberg is the new CEO of Flemingsberg Science. His objectives include attracting more companies to the area and strengthening Flemingsberg’s existing innovation support system.
When this year’s Nobel Prize in Medicine was announced, it was especially good news for AlzeCure in Flemingsberg. This is where a painkiller is being developed based on the breakthrough discovery.
As a student, worker or resident in Flemingsberg you can now compete with your business idea. In a sub-competition to the national business plan competition Venture Cup, Flemingsberg Science rewards ideas that contribute to a better world. In addition to the prize money of SEK 5.000, the winner also gets a rent-free space for three months in Flemingsbergs Sciences' innovation environment.
"Flemingsberg is the place in the world you want to be if you work with NK cells. There is a strong research facility here with a world-leading research group and proximity to a clinic that really knows NK cells. We recently started the construction of a new GMP facility with an associated research laboratory of 350 square meters for our NK cell therapy. The new facility is being built at Novum in Flemingsberg and, once the facility is completed in 2022, it will give us complete control over the entire development chain."
On 1st November, Johnny Högberg will take over as Chief Executive Officer of the Flemingsberg Science Foundation.
Sparly tog hem vinsten i startuptävlingen Flemingsberg Science Award. Förutom prissumman på 10 000 kronor väntar nu fri plats under tre månader i Flemingsberg Sciences innovationsmiljö.